Effectiveness of topiramate in the treatment of pediatric chronic daily headache

John C. Borzy, Thomas K. Koch, James R. Schimschock

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

This study reports on the efficacy and safety of low-dose topiramate in the treatment of pediatric patients with chronic daily headache. Topiramate is one of the new antiepileptic drugs commonly being used for migraine prophylaxis in adults as well as children and was recently approved by the Food and Drug Administration for migraine treatment in adults. This report presents our experience with low-dose topiramate for the treatment of chronic daily headache using a retrospective parental survey of 21 patients ranging in age from 6 to 18 years. Efficacy and safety were evaluated using a parental assessment and satisfaction questionnaire. Sixty-two percent of families reported that low-dose topiramate (average dose of 30 mg/day) was successful in reducing both the frequency and severity of headache episodes. The headache frequency decreased from 22.8 headaches/month to 7.2 headaches/month and severity decreased from a pain score of 8.1 to 3.7. Topiramate was safe, well tolerated, and highly effective at low doses in the treatment of chronic daily headaches.

Original languageEnglish (US)
Pages (from-to)314-316
Number of pages3
JournalPediatric Neurology
Volume33
Issue number5
DOIs
StatePublished - Nov 2005

Fingerprint

Headache Disorders
Headache
Pediatrics
Migraine Disorders
Therapeutics
Safety
United States Food and Drug Administration
Anticonvulsants
topiramate
Pain

ASJC Scopus subject areas

  • Clinical Neurology
  • Pediatrics, Perinatology, and Child Health
  • Developmental Neuroscience
  • Neurology

Cite this

Effectiveness of topiramate in the treatment of pediatric chronic daily headache. / Borzy, John C.; Koch, Thomas K.; Schimschock, James R.

In: Pediatric Neurology, Vol. 33, No. 5, 11.2005, p. 314-316.

Research output: Contribution to journalArticle

Borzy, John C. ; Koch, Thomas K. ; Schimschock, James R. / Effectiveness of topiramate in the treatment of pediatric chronic daily headache. In: Pediatric Neurology. 2005 ; Vol. 33, No. 5. pp. 314-316.
@article{e35185ad0dc24b2e8657a39d225b2c96,
title = "Effectiveness of topiramate in the treatment of pediatric chronic daily headache",
abstract = "This study reports on the efficacy and safety of low-dose topiramate in the treatment of pediatric patients with chronic daily headache. Topiramate is one of the new antiepileptic drugs commonly being used for migraine prophylaxis in adults as well as children and was recently approved by the Food and Drug Administration for migraine treatment in adults. This report presents our experience with low-dose topiramate for the treatment of chronic daily headache using a retrospective parental survey of 21 patients ranging in age from 6 to 18 years. Efficacy and safety were evaluated using a parental assessment and satisfaction questionnaire. Sixty-two percent of families reported that low-dose topiramate (average dose of 30 mg/day) was successful in reducing both the frequency and severity of headache episodes. The headache frequency decreased from 22.8 headaches/month to 7.2 headaches/month and severity decreased from a pain score of 8.1 to 3.7. Topiramate was safe, well tolerated, and highly effective at low doses in the treatment of chronic daily headaches.",
author = "Borzy, {John C.} and Koch, {Thomas K.} and Schimschock, {James R.}",
year = "2005",
month = "11",
doi = "10.1016/j.pediatrneurol.2005.06.001",
language = "English (US)",
volume = "33",
pages = "314--316",
journal = "Pediatric Neurology",
issn = "0887-8994",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Effectiveness of topiramate in the treatment of pediatric chronic daily headache

AU - Borzy, John C.

AU - Koch, Thomas K.

AU - Schimschock, James R.

PY - 2005/11

Y1 - 2005/11

N2 - This study reports on the efficacy and safety of low-dose topiramate in the treatment of pediatric patients with chronic daily headache. Topiramate is one of the new antiepileptic drugs commonly being used for migraine prophylaxis in adults as well as children and was recently approved by the Food and Drug Administration for migraine treatment in adults. This report presents our experience with low-dose topiramate for the treatment of chronic daily headache using a retrospective parental survey of 21 patients ranging in age from 6 to 18 years. Efficacy and safety were evaluated using a parental assessment and satisfaction questionnaire. Sixty-two percent of families reported that low-dose topiramate (average dose of 30 mg/day) was successful in reducing both the frequency and severity of headache episodes. The headache frequency decreased from 22.8 headaches/month to 7.2 headaches/month and severity decreased from a pain score of 8.1 to 3.7. Topiramate was safe, well tolerated, and highly effective at low doses in the treatment of chronic daily headaches.

AB - This study reports on the efficacy and safety of low-dose topiramate in the treatment of pediatric patients with chronic daily headache. Topiramate is one of the new antiepileptic drugs commonly being used for migraine prophylaxis in adults as well as children and was recently approved by the Food and Drug Administration for migraine treatment in adults. This report presents our experience with low-dose topiramate for the treatment of chronic daily headache using a retrospective parental survey of 21 patients ranging in age from 6 to 18 years. Efficacy and safety were evaluated using a parental assessment and satisfaction questionnaire. Sixty-two percent of families reported that low-dose topiramate (average dose of 30 mg/day) was successful in reducing both the frequency and severity of headache episodes. The headache frequency decreased from 22.8 headaches/month to 7.2 headaches/month and severity decreased from a pain score of 8.1 to 3.7. Topiramate was safe, well tolerated, and highly effective at low doses in the treatment of chronic daily headaches.

UR - http://www.scopus.com/inward/record.url?scp=27144473871&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27144473871&partnerID=8YFLogxK

U2 - 10.1016/j.pediatrneurol.2005.06.001

DO - 10.1016/j.pediatrneurol.2005.06.001

M3 - Article

C2 - 16243217

AN - SCOPUS:27144473871

VL - 33

SP - 314

EP - 316

JO - Pediatric Neurology

JF - Pediatric Neurology

SN - 0887-8994

IS - 5

ER -